Proactive Investors - Run By Investors For Investors
Why invest in ETX?
e-Therapeutics plc: THE INVESTMENT CASE

e-Therapeutics in £2.3mln search engine technology deal

Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007
stylised picture with web icons meant to denote a web search
The company is buying back a web search firm.

The drug discovery group e-Therapeutics PLC (LON:ETX) has announced a deal to acquire a developer of search engine technology for up to £2.32mln.

Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007.

Searchbolt’s main asset is an exclusive licence to use the technology ETX deploys in network pharmacology used to identify drug candidates.

The deal is partly defensive as it brings under one roof all the intellectual property related to treatments it may soon commercialise.

But the AIM-listed group has also identified the potential to use of Searchbolt in the field of social media.

ETX chief executive Malcolm Young owns around 32% of Searchbolt, and will receive initial payment for his stake mainly in shares.

About the company

The drug developer is making significant progress and is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.

ETX is a drug discoverer with a proprietary platform based on advances in network pharmacology, an approach which analyses how disease patterns work.

So far, the engine, which is the group's core focus, has identified thousands of new molecules in medical and commercial areas.

But it is now focused on discoveries in the immuno-oncology space, currently a buzz area, which is focused on drug resistance to targeted cancer therapies.

It is worth noting, that the firm's platform is generating multiple and potent molecules in this field - more than for conventional drug discovery.

Its drug pipeline

The firm has finished a phase IIb trial on its most advanced candidate for a major depressive disorder -  ETS6103 is now complete and results support the target product profile and it is now progressing sets to potentially out-license the drug.

It showed fewer side effects and better tolerance profile than current post-SSRI treatment (a class of drugs often used as first-line antidepressants, such as amitriptyline).

Phase I clinical trials in cancer for flagship candidate ETS2101 are now complete for treating hepatocellular carcinoma and pancreatic cancer and established an acceptable dose for this product candidate and important information about how it would be taken by the patient. 


Register here to be notified of future ETX Company articles
View full ETX profile View Profile

e-Therapeutics plc Timeline

September 20 2016

Related Articles

October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
picture of an affimer
April 03 2017
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use